iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
UK NICE NHS Recommends Epclusa
  Sofosbuvir-velpatasvir for treating chronic hepatitis C
Technology appraisal guidance [TA430] Published date: 25 January 2017
What does this mean for me?
If you have chronic hepatitisC, and your doctor thinks that sofosbuvir-velpatasvir is the right treatment, you should be able to have it on the NHS.
Sofosbuvir-velpatasvir should be available on the NHS within 3months. If you are not eligible for treatment as described above, you should be able to continue taking sofosbuvir-velpatasvir until you and your doctor decide it is the right time to stop.
Sofosbuvir-velpatasvir (Epclusa) is recommended as a possible treatment for chronic hepatitisC in adults. See table1.


The condition and the treatment
HepatitisC is a disease of the liver that is caused by the hepatitisC virus. There are 6different types of the virus. Some people who are infected with the hepatitisC virus get rid of it quickly without treatment but most people develop a long-lasting infection; this is called chronic hepatitisC. People who have chronic hepatitisC may feel well for many years, but the virus can cause liver damage (cirrhosis or scarring) later and can make them feel ill. In compensated cirrhosis, the liver is able to work well enough despite the damage. In decompensated cirrhosis the liver stops working properly.
Sofosbuvir-velpatasvir and interferon are drugs used to treat certain types of the hepatitisC virus. They are sometimes taken with another drug, called ribavirin. They can get rid of the virus in people who have never had treatment or who have had treatment before that didn't get rid of the virus.
Evidence-based recommendations on sofosbuvir-velpatasvir (Epclusa) for treating chronic hepatitisC in adults.
Review and download supporting evidence. Includes the full guideline if available
Committee papers 13 December 2016 1.5 MB
Committee papers Slides 13 December 2016 824.47 KB

  iconpaperstack View Older Articles   Back to Top   www.natap.org